A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer.

Trial Profile

A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Fulvestrant (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms FIRST
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 10 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 11 Oct 2016 Results of analysis assessing relationship between progression-free survival and overall survival in patients receiving first-line treatment with fulvestrant or anastrozole, presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top